High-Confidence Cancer Patient Stratification Through Multiomics Investigation of DNA Repair Disorders

    November 2022 in “ Cell Death and Disease ”
    Garik V. Mkrtchyan, Alexander Veviorskiy, Evgeny Izumchenko, Anastasia Shneyderman, Frank W. Pun, Ivan V. Ozerov, Alex Aliper, Alex Zhavoronkov, Morten Scheibye‐Knudsen
    Image of study
    TLDR CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
    The study utilized the AI-driven PandaOmics platform to investigate gene expression changes in DNA repair-deficient disorders, identifying CEP135 as a potential biomarker for cancer patient stratification. High CEP135 expression was associated with poorer survival in sarcoma and glioma patients, suggesting its use as a prognostic biomarker. The study also identified polo-like kinase 1 (PLK1) as a promising therapeutic target for sarcoma patients with high CEP135 expression, as its inhibition significantly reduced cell growth in experimental models. The research highlighted the potential of AI-driven multiomics analysis for discovering novel cancer biomarkers and therapeutic targets, although further validation was needed.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results